inclusion criteria: 1. subject (or legally authorized representative) provides written informed consent prior to initiation of any study procedures. 2. understands and agrees to comply with planned study procedures. 3. adult ≥18 years of age at time of enrollment. 4. subject consents to randomization. 5. subject has confirmed covid-19 disease \< 72 hours prior to randomization. 6. subject has been experiencing symptoms for \>1 day but ≤7 days. 7. able to use an electronic tablet and bluetooth devices. 8. subject has mild to moderate covid-19 which is defined as (equivalent to 1, 2 on the who scale): 1. patient does not require immediate admission to the hospital within 24 hrs of initial assessment 2. patient does not require supplemental oxygen due to covid-19 3. patient has a score of 2 ("moderate") in at least 3 of the symptoms in the covid- 19 symptom score

inclusion criteria: 1. subject (or legally authorized representative) provides written informed consent prior to initiation of any study procedures. 2. understands and agrees to comply with planned study procedures. 3. adult ≥18 years of age at time of enrollment. 4. subject consents to randomization. 5. subject has confirmed covid-19 disease \< 72 hours prior to randomization. 6. subject has been experiencing symptoms for \>1 day but ≤7 days. 7. able to use an electronic tablet and bluetooth devices. 8. subject has mild to moderate covid-19 which is defined as (equivalent to 1, 2 on the who scale): 1. patient does not require immediate admission to the hospital within 24 hrs of initial assessment 2. patient does not require supplemental oxygen due to covid-19 3. patient has a score of 2 ("moderate") in at least 3 of the symptoms in the covid- 19 symptom score

inclusion criteria: subject (or legally authorized representative) provides written informed consent prior to initiation of any study procedures. understands and agrees to comply with planned study procedures. adult ≥18 years of age at time of enrollment. subject consents to randomization. subject has confirmed covid-19 disease < 72 hours prior to randomization. subject has been experiencing symptoms for >1 day but ≤7 days. able to use an electronic tablet and bluetooth devices. subject has mild to moderate covid-19 which is defined as (equivalent to 1, 2 on the who scale): patient does not require immediate admission to the hospital within 24 hrs of initial assessment patient does not require supplemental oxygen due to covid-19 patient has a score of 2 ("moderate") in at least 3 of the symptoms in the covid- 19 symptom score

inclusion criteria: subject (or legally authorized representative) provides written informed consent prior to initiation of any study procedures. understands and agrees to comply with planned study procedures. adult ≥18 years of age at time of enrollment. subject consents to randomization. subject has confirmed covid-19 disease < 72 hours prior to randomization. subject has been experiencing symptoms for >1 day but ≤7 days. able to use an electronic tablet and bluetooth devices. subject has mild to moderate covid-19 which is defined as (equivalent to 1, 2 on the who scale): patient does not require immediate admission to the hospital within 24 hrs of initial assessment patient does not require supplemental oxygen due to covid-19 patient has a score of 2 ("moderate") in at least 3 of the symptoms in the covid- 19 symptom score

inclusion criteria: 1. subject (or legally authorized representative) provides written informed consent prior to initiation of any study procedures. 2. understands and agrees to comply with planned study procedures. 3. adult ≥18 years of age at time of enrollment. 4. subject consents to randomization. 5. subject has confirmed covid-19 disease < 72 hours prior to randomization. 6. subject has been experiencing symptoms for >1 day but ≤7 days. 7. able to use an electronic tablet and bluetooth devices. 8. subject has mild to moderate covid-19 which is defined as (equivalent to 1, 2 on the who scale): 1. patient does not require immediate admission to the hospital within 24 hrs of initial assessment 2. patient does not require supplemental oxygen due to covid-19 3. patient has a score of 2 ("moderate") in at least 3 of the symptoms in the covid- 19 symptom score

inclusion criteria: 1. subject (or legally authorized representative) provides written informed consent prior to initiation of any study procedures. 2. understands and agrees to comply with planned study procedures. 3. adult ≥18 years of age at time of enrollment. 4. subject consents to randomization. 5. subject has confirmed covid-19 disease < 72 hours prior to randomization. 6. subject has been experiencing symptoms for >1 day but ≤7 days. 7. able to use an electronic tablet and bluetooth devices. 8. subject has mild to moderate covid-19 which is defined as (equivalent to 1, 2 on the who scale): 1. patient does not require immediate admission to the hospital within 24 hrs of initial assessment 2. patient does not require supplemental oxygen due to covid-19 3. patient has a score of 2 ("moderate") in at least 3 of the symptoms in the covid- 19 symptom score

inclusion criteria: 1. subject (or legally authorized representative) provides written informed consent prior to initiation of any study procedures. 2. understands and agrees to comply with planned study procedures. 3. adult ≥18 years of age at time of enrollment. 4. subject consents to randomization. 5. subject has pcr confirmed covid-19 disease < 72 hours prior to randomization. 6. subject has been experiencing symptoms for >1 day but ≤4 days. 7. able to use an electronic tablet and bluetooth devices. 8. subject has mild to moderate covid-19 which is defined as (equivalent to 1, 2 on the who scale): 1. patient does not require immediate admission to the hospital within 24 hrs of initial assessment 2. patient does not require supplemental oxygen due to covid-19 3. patient has a score of 2 ("moderate") in at least 3 of the symptoms in the covid- 19 symptom score

inclusion criteria: 1. subject (or legally authorized representative) provides written informed consent prior to initiation of any study procedures. 2. understands and agrees to comply with planned study procedures. 3. adult ≥18 years of age at time of enrollment. 4. subject consents to randomization. 5. subject has pcr confirmed covid-19 disease < 72 hours prior to randomization. 6. subject has been experiencing symptoms for >1 day but ≤4 days. 7. able to use an electronic tablet and bluetooth devices. 8. subject has mild to moderate covid-19 which is defined as (equivalent to 1, 2 on the who scale): 1. patient does not require immediate admission to the hospital within 24 hrs of initial assessment 2. patient does not require supplemental oxygen due to covid-19 3. patient has a score of 2 ("moderate") in at least 3 of the symptoms in the covid- 19 symptom score